Archer, David F.

Archer, David F.
Close

Contact Info

archerdf@evms.edu

EVMS Directory Profile

overview

David F. Archer, MD is an Obstetrician/Gynecologist with advanced certification in Reproductive Endocrinology and Infertility. He has been a Principal Investigator or Investigator on 337 Clinical Trials related to Women's Health for the past 32 years. He is a Principal Investigator for the NICHD Contraceptive Clinical Trials Network since 1996, and was the Director of the CONRAD Clinical Research Center for 30 years. He has also been involved in general gynecology clinical trials of endometriosis and uterine myomas using gonadotropin releasing hormone agonists, non-peptide gonadotropin releasing hormone antagonists, selective progesterone receptor modulators, and anti-fibrinolytic medication for management of pain, heavy menstrual bleeding and other clinical symptoms and physical findings.

Dr. Archer is interested in the role of the plasminogen activator system in unscheduled endometrial bleeding in contraceptive users and women with heavy menstrual bleeding. The role of glycosylated Follicle stimulating Hormone in age related infertility, the menopause transition and menopause itself is a new focus of research.

Dr. Archer is an active member of multiple national and international societies related to women's health. He has been an officer or member of the Board of the American Society of Reproductive Medicine, the North American Menopause Society, International Menopause Society, European Society for Contraception and Reproductive Health and the Egon and Ann Diczfalusy Foundation.

selected publications

2021

Drospirenone Effects on the Plasminogen Activator System in Immortalized Human Endometrial Endothelial Cells. REPRODUCTIVE SCIENCES.
Full Text via DOI: 10.1007/s43032-020-00433-x PMID: 33559058
2021

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix. JOURNAL OF PAIN RESEARCH. 14:263-271.
Full Text via DOI: 10.2147/JPR.S284703 PMID: 33564263
2021

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 224.
Full Text via DOI: 10.1016/j.ajog.2020.07.032 PMID: 32702363
2020

A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause. CLIMACTERIC. 23:306-310.
Full Text via DOI: 10.1080/13697137.2020.1727878 PMID: 32107942
2020

Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. NEW ENGLAND JOURNAL OF MEDICINE. 382:328-340.
Full Text via DOI: 10.1056/NEJMoa1904351 PMID: 31971678
2020

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).. Menopause (New York, N.Y.). 410-417.
Full Text via DOI: 10.1097/GME.0000000000001480 PMID: 31913228
2020

Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. CONTRACEPTION. 102:168-173.
Full Text via DOI: 10.1016/j.contraception.2020.05.004
2019

Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS. 11:171-180.
Full Text via DOI: 10.1177/2284026519872401
2019

TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women. CLIMACTERIC. 22:412-418.
Full Text via DOI: 10.1080/13697137.2019.1577379 PMID: 30862193
2019

A combined, bioidentical, oral, 17 beta-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 12:729-739.
Full Text via DOI: 10.1080/17512433.2019.1637731 PMID: 31282768
2019

Comparison of self-reported female condom failure and biomarker-confirmed semen exposure. CONTRACEPTION. 100:406-412.
Full Text via DOI: 10.1016/j.contraception.2019.07.143 PMID: 31381878
2019

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 26:611-621.
Full Text via DOI: 10.1097/GME.0000000000001292 PMID: 30694917
2019

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. LANCET GLOBAL HEALTH. 7:E1054-E1064.
Full Text via DOI: 10.1016/S2214-109X(19)30265-7 PMID: 31231065
2019

Elagolix suppresses ovulation in a dose-dependent manner: Results from a 3-month, randomized study in ovulatory women.. The Journal of clinical endocrinology and metabolism.
Full Text via DOI: 10.1210/clinem/dgz086 PMID: 31650182
2019

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM. 14:301-314.
Full Text via DOI: 10.1080/17446651.2019.1657008 PMID: 31526199
2018

Estradiol vaginal inserts (4 mu g and 10 mu g) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. CURRENT MEDICAL RESEARCH AND OPINION. 2131-2136.
Full Text via DOI: 10.1080/03007995.2018.1527578 PMID: 30238814
2018

Effects of Single-Capsule 17 beta-Estradiol/Progesterone (TX-001HR) on Weight and Blood Pressure in Menopausal Women of the REPLENISH Trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1496-1497.
2018

Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: A phase 3, Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1501-1501.
2018

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas A Randomized Controlled Trial. OBSTETRICS AND GYNECOLOGY. 132:1252-1264.
Full Text via DOI: 10.1097/AOG.0000000000002933 PMID: 30303923
2018

Safety and efficacy results for the segesterone acetate ethinyl estradiol (SA/EE) contraceptive vaginal ring. CONTRACEPTION. 336-336.
Full Text via DOI: 10.1016/j.contraception.2018.07.024
2018

BONE TURNOVER CHANGES IN WOMEN TREATED WITH ELAGOLIX OR PLACEBO DURING THE ELARIS EM-I AND EM-II TRIALS WHO DID NOT CONTINUE IN THE EXTENSION STUDIES.. FERTILITY AND STERILITY. E12-E12.
2018

EFFECT OF ORAL ESTRADIOL AND PROGESTERONE THERAPY ON VAGINAL CYTOKINES IN POSTMENOPAUSAL WOMEN.. FERTILITY AND STERILITY. E286-E286.
2018

ELAGOLIX REDUCED DYSPAREUNIA AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PREMENOPAUSAL WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.. FERTILITY AND STERILITY. E82-E83.
2018

ESTRADIOL LEVELS ARE DIFFERENTIALLY SUPPRESSED BY ELAGOLIX COMPARED TO LEUPROLIDE ACETATE.. FERTILITY AND STERILITY. E12-E13.
2018

Morbid obesity: potential effects of hormonal contraception. CONTRACEPTION. 174-180.
Full Text via DOI: 10.1016/j.contraception.2018.05.008 PMID: 29777662
2018

Untitled. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 952-953.
2018

A 17 beta-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women. OBSTETRICS AND GYNECOLOGY. 132:161-170.
Full Text via DOI: 10.1097/AOG.0000000000002645 PMID: 29889748
2018

Long-Term Outcomes of Elagolix in Women With Endometriosis. OBSTETRICS AND GYNECOLOGY. 132:147-160.
Full Text via DOI: 10.1097/AOG.0000000000002675 PMID: 29889764
2018

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 837-847.
Full Text via DOI: 10.1097/GME.0000000000001138 PMID: 29870471
2018

Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 25:762-766.
Full Text via DOI: 10.1097/GME.0000000000001081 PMID: 29509598
2018

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone (R) and estradiol: pharmacokinetics from a dose-finding study. CONTRACEPTION. 97:422-427.
Full Text via DOI: 10.1016/j.contraception.2018.01.012 PMID: 29409834
2018

Long-term Effect of Elagolix on Bone Mineral Density in Women with Endometriosis-Associated Pain. OBSTETRICS AND GYNECOLOGY. 86S-87S.
Full Text via DOI: 10.1097/01.AOG.0000533387.12236.72
2018

A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 25:133-138.
Full Text via DOI: 10.1097/GME.0000000000000985 PMID: 28926514
2018

Doxycycline Alters the Expression of Matrix Metalloproteases in the Endometrial Cells Exposed to Ovarian Steroids and Pro-inflammatory Cytokine (Retraction of Vol 73, Pg 118, 2017). JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 106-106.
Full Text via DOI: 10.1016/j.jri.2017.11.002 PMID: 29406209
2018

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 25:1339-1353.
Full Text via DOI: 10.1097/GME.0000000000001238 PMID: 30358731
2018

Human vaginal pH and microbiota: an update. GYNECOLOGICAL ENDOCRINOLOGY. 34:451-455.
Full Text via DOI: 10.1080/09513590.2017.1407753 PMID: 29271266
2018

Untitled. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 952-953.
Full Text via DOI: 10.1097/GME.0000000000001146 PMID: 29944639
2017

17 beta-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1430-+.
2017

A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom. JOURNAL OF WOMENS HEALTH. 27:231-237.
Full Text via DOI: 10.1089/jwh.2017.6515 PMID: 29193980
2017

Concerns with Long-Term Estrogen Exposure, Inconsistent Treatment Use, and Reduced Quality of Life in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1445-1446.
2017

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1431-1432.
2017

Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 mu g estradiol on symptoms of vulvovaginal atrophy. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 1-8.
Full Text via DOI: 10.1016/j.jsbmb.2017.03.014 PMID: 28323042
2017

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. CLIMACTERIC. 20:402-413.
Full Text via DOI: 10.1080/13697137.2017.1362156 PMID: 28805475
2017

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1101-1112.
Full Text via DOI: 10.1097/GME.0000000000000983 PMID: 28872490
2017

BLEEDING AND SPOTTING WITH 180 DAYS' CONTINUOUS USE OF A COMBINED NESTORONE/ESTRADIOL CONTRACEPTIVE VAGINAL RING. FERTILITY AND STERILITY. E11-E11.
2017

ELAGOLIX IMPROVES QUALITY OF LIFE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS: EVIDENCE FROM A PHASE 2B RANDOMIZED TRIAL.. FERTILITY AND STERILITY. E27-E27.
2017

LONG-TERM EFFECT OF ELAGOLIX ON BONE MINERAL DENSITY: RESULTS FROM TWO PHASE 3 EXTENSION STUDIES IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.. FERTILITY AND STERILITY. E95-E95.
2017

THE EFFECTS OF THE ETONOGESTREL 0.12MG/ETHINYL ESTRADIOL 0.015MG VAGINAL RING (NUVARING (R)) ON INFLAMMATORY BIOMARKERS. FERTILITY AND STERILITY. E121-E121.
2017

USE OF PEAK DRUG LEVELS TO ASSESS COMPLIANCE WITH VAGINAL RING CONTRACEPTION.. FERTILITY AND STERILITY. E12-E12.
2017

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 24:1003-1010.
Full Text via DOI: 10.1097/GME.0000000000000880 PMID: 28419068
2017

LETTERS TO THE EDITOR Reply. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 988-989.
2017

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. NEW ENGLAND JOURNAL OF MEDICINE. 377:28-40.
Full Text via DOI: 10.1056/NEJMoa1700089 PMID: 28525302
2017

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. FERTILITY AND STERILITY. 108:152-+.
Full Text via DOI: 10.1016/j.fertnstert.2017.05.006 PMID: 28579415
2017

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. JOURNAL OF WOMENS HEALTH. 26:616-623.
Full Text via DOI: 10.1089/jwh.2016.6187 PMID: 28355090
2017

A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review. MATURITAS. 51-58.
Full Text via DOI: 10.1016/j.maturitas.2017.02.008 PMID: 28364869
2017

REPLENISH Trial: Combination Capsule of Estradiol/Progesterone (TX-001HR) for Treating Hot Flushes. OBSTETRICS AND GYNECOLOGY. 133S-134S.
Full Text via DOI: 10.1097/01.AOG.0000514678.75674.b8
2017

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 24:510-516.
Full Text via DOI: 10.1097/GME.0000000000000790 PMID: 28002201
2017

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 24:409-416.
Full Text via DOI: 10.1097/GME.0000000000000786 PMID: 27922936
2017

Dose-Dependent Suppression of Ovulation and Ovarian Activity by Elagolix in Healthy Premenopausal Women.. REPRODUCTIVE SCIENCES. 140A-140A.
2017

Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 24:1246-1256.
Full Text via DOI: 10.1097/GME.0000000000000910 PMID: 28640161
2017

Heavy menstrual bleeding diagnosis and medical management.
Full Text via DOI: 10.1186/s40834-017-0047-4 PMID: 29201425
2017

LETTERS TO THE EDITOR Reply. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 988-989.
Full Text via DOI: 10.1097/GME.0000000000000940 PMID: 28719419
2017

Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 24:1167-1174.
Full Text via DOI: 10.1097/GME.0000000000000900 PMID: 28509812
2017

Safety and benefit considerations for menopausal hormone therapy. EXPERT OPINION ON DRUG SAFETY. 941-954.
Full Text via DOI: 10.1080/14740338.2017.1343298 PMID: 28664754
2017

Science of intracrinology in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 702-712.
Full Text via DOI: 10.1097/GME.0000000000000808 PMID: 28098598
2016

Significant Improvement in Vaginal Epithelium with TX-004HR in Postmenopausal Women with Moderate-to-Severe Vulvar and Vaginal Atrophy (VVA) and Dyspareunia. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1372-1372.
2016

TX-004HR Improves Vaginal Physiology and Dyspareunia with Negligible Systemic Absorption. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1371-1371.
2016

TX-004HR Provides Robust Efficacy for Symptomatic Postmenopausal Vulvar and Vaginal Atrophy (VVA) while Providing Negligible to Very Low Systemic Absorption of Estradiol: Results of Clinical Phase 2 and 3 Trials. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1374-1375.
2016

Assessment of the vaginal residence time of biomarkers of semen exposure. CONTRACEPTION. 94:512-520.
Full Text via DOI: 10.1016/j.contraception.2016.05.012 PMID: 27259675
2016

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. JOURNAL OF WOMENS HEALTH. 25:1102-1111.
Full Text via DOI: 10.1089/jwh.2015.5558 PMID: 27676118
2016

The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells. REPRODUCTIVE SCIENCES. 23:1536-1541.
Full Text via DOI: 10.1177/1933719116645193 PMID: 27130232
2016

Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies. AIDS RESEARCH AND HUMAN RETROVIRUSES. 53-53.
2016

Prescribing of FDA-approved and compounded hormone therapy differs by specialty. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 23:1075-1082.
Full Text via DOI: 10.1097/GME.0000000000000683 PMID: 27648594
2016

THE EFFECT OF ELAGOLIX ON BONE MINERAL DENSITY: SAFETY RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.. FERTILITY AND STERILITY. E276-E277.
2016

Activity of CYP3A4 and CYP2C19 in Young Women Who Use Depot Medroxyprogesterone Acetate (DMPA). OBSTETRICS AND GYNECOLOGY. 120S-121S.
2016

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. JOURNAL OF WOMENS HEALTH. 25:431-442.
Full Text via DOI: 10.1089/jwh.2015.5351 PMID: 27058301
2016

Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. GYNECOLOGICAL ENDOCRINOLOGY. 32:240-245.
Full Text via DOI: 10.3109/09513590.2015.1110140 PMID: 26634942
2016

Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive. CONTRACEPTION. 93:52-57.
Full Text via DOI: 10.1016/j.contraception.2015.09.013 PMID: 26410176
2016

Does laryngoscopic view after intubation predict laryngoscopic view before intubation?. JOURNAL OF CLINICAL ANESTHESIA. 33:469-475.
Full Text via DOI: 10.1016/j.jclinane.2016.04.037 PMID: 27555212
2016

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION. 25:181-190.
Full Text via DOI: 10.1515/hmbci-2015-0044 PMID: 26725467
2016

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 23:243-256.
Full Text via DOI: 10.1097/GME.0000000000000571 PMID: 26731686
2016

Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone (R) and ethinyl estradiol. CONTRACEPTION. 93:58-64.
Full Text via DOI: 10.1016/j.contraception.2015.09.008 PMID: 26408374
2016

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 23:957-964.
Full Text via DOI: 10.1097/GME.0000000000000656 PMID: 27404027
2016

Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 159:142-153.
Full Text via DOI: 10.1016/j.jsbmb.2016.03.016 PMID: 26972555
2016

The effect of dalteparin on thromboelastography in pregnancy: an in vitro study. INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA. 28:22-27.
Full Text via DOI: 10.1016/j.ijoa.2016.08.002 PMID: 27717636
2016

Untitled. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 471-472.
Full Text via DOI: 10.1097/GME.0000000000000638 PMID: 26908208
2015

Effects of Ospemifene on Lipid and Coagulation Parameters in Postmenopausal Women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1375-1375.
2015

Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. CONTRACEPTION. 92:439-444.
Full Text via DOI: 10.1016/j.contraception.2015.07.014 PMID: 26232513
2015

Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 22:1067-1075.
Full Text via DOI: 10.1097/GME.0000000000000436 PMID: 25756697
2015

ELAGOLIX FOR THE MANAGEMENT OF HEAVY MENSTRUAL BLEEDING (HMB) ASSOCIATED WITH UTERINE FIBROIDS (UF): RESULTS FROM A PHASE 2A PROOF-OF-CONCEPT STUDY. FERTILITY AND STERILITY. E70-E71.
2015

ESTRADIOL VERSUS TRANEXAMIC ACID ON THE AMOUNT AND DURATION OF ACUTE CYCLIC HEAVY MENSTRUAL BLEEDING.. FERTILITY AND STERILITY. E171-E171.
2015

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 22:950-963.
Full Text via DOI: 10.1097/GME.0000000000000428 PMID: 25734980
2015

Insight into the biogenesis of tax nuclear speckles using comparative interactome analysis. RETROVIROLOGY.
2015

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. CLIMACTERIC. 18:590-607.
Full Text via DOI: 10.3109/13697137.2014.992012 PMID: 25511551
2015

Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system. EXPERT OPINION ON PHARMACOTHERAPY. 1901-1909.
Full Text via DOI: 10.1517/14656566.2015.1056733 PMID: 26194214
2015

Vaginal atrophy and disease susceptibility: the role of leukocytes. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 804-805.
Full Text via DOI: 10.1097/gme.0000000000000513 PMID: 26154272
2015

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 786-796.
Full Text via DOI: 10.1097/GME.0000000000000365 PMID: 25423325
2015

17 beta-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. MATURITAS. 28-35.
Full Text via DOI: 10.1016/j.maturitas.2015.02.266 PMID: 25835751
2015

A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. CONTRACEPTION. 360-367.
Full Text via DOI: 10.1016/j.contraception.2015.01.008 PMID: 25596512
2015

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. MATURITAS. 81:46-56.
Full Text via DOI: 10.1016/j.maturitas.2015.02.005 PMID: 25771041
2015

Prevalence of Use and Cost of Compounded Menopausal Hormone Therapy. OBSTETRICS AND GYNECOLOGY. 98S-98S.
2015

Contraceptive Efficacy, Safety, Fit, and Acceptability of a Single-Size Diaphragm Developed With End-User Input. OBSTETRICS AND GYNECOLOGY. 125:895-903.
Full Text via DOI: 10.1097/AOG.0000000000000721 PMID: 25751199
2015

Risks of Sex Hormone Therapy in Women: Important Lessons from the Transgender Woman Literature Response. SOUTHERN MEDICAL JOURNAL. 242-243.
2015

Vaginal cytokines do not correlate with postmenopausal vulvovaginal symptoms. GYNECOLOGICAL ENDOCRINOLOGY. 31:317-321.
Full Text via DOI: 10.3109/09513590.2014.995080 PMID: 25559048
2015

Impact of a One-Year Contraceptive Vaginal Ring Delivering Nestorone and Ethinyl Estradiol on Hepatic Estrogen-Sensitive Proteins. REPRODUCTIVE SCIENCES. 111A-112A.
2015

New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study. CONTRACEPTION. 91:211-216.
Full Text via DOI: 10.1016/j.contraception.2014.11.013 PMID: 25586864
2015

Recent advances help understand and improve the safety of menopausal therapies. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 351-360.
Full Text via DOI: 10.1097/gme.0000000000000292 PMID: 25051290
2015

Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 212.
Full Text via DOI: 10.1016/j.ajog.2014.09.014 PMID: 25220709
2015

Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill. CONTRACEPTION. 91:204-210.
Full Text via DOI: 10.1016/j.contraception.2014.11.011 PMID: 25582984
2015

Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 139-143.
Full Text via DOI: 10.1016/j.jsbmb.2014.09.003 PMID: 25201455
2015

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. JOURNAL OF SEXUAL MEDICINE. 12:2401-2412.
Full Text via DOI: 10.1111/jsm.13045 PMID: 26597311
2015

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 22:36-43.
Full Text via DOI: 10.1097/gme.0000000000000275 PMID: 24977459
2015

Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. CLIMACTERIC. 18:817-825.
Full Text via DOI: 10.3109/13697137.2015.1077508 PMID: 26517756
2015

Interrelationships of Sex, Physician-Diagnosed Arthritis, Chronic Inflammation, and Physical Functioning in the Third National Health and Nutrition Examination Surveys.. GERONTOLOGY AND GERIATRIC MEDICINE. 2333721415591680.
Full Text via DOI: 10.1177/2333721415591680 PMID: 28138457
2015

Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 22:1289-1295.
Full Text via DOI: 10.1097/GME.0000000000000470 PMID: 25968836
2015

Risks of Sex Hormone Therapy in Women: Important Lessons from the Transgender Woman Literature Response. SOUTHERN MEDICAL JOURNAL. 242-243.
Full Text via DOI: 10.14423/SMJ.0000000000000271 PMID: 25871997
2015

Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 154:186-196.
Full Text via DOI: 10.1016/j.jsbmb.2015.08.016 PMID: 26291918
2015

Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION. 24:117-129.
Full Text via DOI: 10.1515/hmbci-2015-0035 PMID: 26509785
2014

Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies. PLOS ONE. 9.
Full Text via DOI: 10.1371/journal.pone.0114368 PMID: 25489736
2014

Effect of Ospemifene on Vasomotor Symptoms in Postmenopausal Women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1359-1359.
2014

Incidence of Endometrial Spotting and Bleeding during Continuous Combined Estrogen plus Progestin Therapy in Normotensive versus Hypertensive Postmenopausal Women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1364-1364.
2014

Ospemifene Improved The Severity of Vulvar and Vaginal Atrophy Symptoms In Postmenopausal Women In Phase 3 Randomized, Placebo-Controlled Trials. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1332-1332.
2014

Responder Analysis of Ospemifene Treatment for Vulvar and Vaginal Atrophy in Postmenopausal Women in Phase 3 Randomized, Placebo-Controlled Trials. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1332-1332.
2014

Commentary on "Menopausal Hormone Treatment in Postmenopausal Women: Risks and Benefits". SOUTHERN MEDICAL JOURNAL. 696-697.
2014

Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure. AIDS RESEARCH AND HUMAN RETROVIRUSES. A172-A172.
2014

GLOBAL ENDOMETRIAL GENE EXPRESSION WITH CONTINUOUS EXPOSURE TO LEVONORGESTREL (LNG) VIA AN INTRAUTERINE SYSTEM (IUS).. FERTILITY AND STERILITY. E141-E141.
2014

LEVONORGESTREL DECREASES TISSUE PLASMINOGEN ACTIVATOR LEVELS THROUGH THE ANDROGEN RECEPTOR IN HUMAN ENDOMETRIAL ENDOTHELIAL CELLS.. FERTILITY AND STERILITY. E270-E271.
2014

Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing. AIDS RESEARCH AND HUMAN RETROVIRUSES. A37-A37.
2014

Differential effects of menopausal therapies on the endometrium. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 21:899-908.
Full Text via DOI: 10.1097/gme.0000000000000186 PMID: 24518153
2014

Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 21:840-845.
Full Text via DOI: 10.1097/gme.0000000000000179 PMID: 24398407
2014

Lack of Influence of Dyspareunia on the Beneficial Effect of Intravaginal Prasterone (Dehydroepiandrosterone, DHEA) on Sexual Dysfunction in Postmenopausal Women. JOURNAL OF SEXUAL MEDICINE. 11:1766-1785.
Full Text via DOI: 10.1111/jsm.12517 PMID: 24774442
2014

Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill: A Randomized Controlled Trial Reply. OBSTETRICS AND GYNECOLOGY. 1108-1108.
2014

Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations. CONTRACEPTION. 242-252.
Full Text via DOI: 10.1016/j.contraception.2013.12.003 PMID: 24485094
2014

A randomized, double- blind, placebo- controlled study of the lowest effective dose of drospirenone with 17 beta- estradiol for moderate to severe vasomotor symptoms in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 21:227-235.
Full Text via DOI: 10.1097/GME.0b013e31829c1431 PMID: 23963307
2014

COX-2, NF-kappa B, and IL-8 Expression in the Placenta in Severe Preeclampsia. REPRODUCTIVE SCIENCES. 190A-190A.
2014

Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17 beta-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 21:236-242.
Full Text via DOI: 10.1097/GME.0b013e31829c12e8 PMID: 23963309
2014

Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 99:E189-E198.
Full Text via DOI: 10.1210/jc.2013-1707 PMID: 24438370
2014

Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill A Randomized Controlled Trial. OBSTETRICS AND GYNECOLOGY. 123:295-303.
Full Text via DOI: 10.1097/AOG.0000000000000095 PMID: 24402597
2014

RE: Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.
Full Text via DOI: 10.1093/jnci/djt372 PMID: 24363446
2014

Commentary on "Menopausal Hormone Treatment in Postmenopausal Women: Risks and Benefits". SOUTHERN MEDICAL JOURNAL. 696-697.
Full Text via DOI: 10.14423/SMJ.0000000000000191 PMID: 25365436
2014

Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill: A Randomized Controlled Trial Reply. OBSTETRICS AND GYNECOLOGY. 1108-1108.
Full Text via DOI: 10.1097/AOG.0000000000000248 PMID: 24785870
2014

Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. CONTRACEPTION. 89:31-35.
Full Text via DOI: 10.1016/j.contraception.2013.07.002 PMID: 23993431
2013

Safety of Oral Ospemifene in Phase 2/3 Placebo-controlled Clinical Trials. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1322-1322.
2013

Vaginal and systemic cytokines in postmenopausal women with and without symptoms of vulvovaginal irritation. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1332-1332.
2013

Toward Early Safety Alert Endpoints: Exploring Biomarkers Suggestive of Microbicide Failure. AIDS RESEARCH AND HUMAN RETROVIRUSES. 29:1475-1486.
Full Text via DOI: 10.1089/aid.2012.0345 PMID: 23885658
2013

A statement on abortion by 100A professors of obstetrics: 40 years later. CONTRACEPTION. 88:568-576.
Full Text via DOI: 10.1016/j.contraception.2013.07.003 PMID: 24034806
2013

A statement on abortion by 100 professors of obstetrics: 40 years later. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 193-199.
Full Text via DOI: 10.1016/j.ajog.2013.03.007 PMID: 23500455
2013

Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive. OBSTETRICS AND GYNECOLOGY. 122:601-607.
Full Text via DOI: 10.1097/AOG.0b013e3182a1741c PMID: 23921878
2013

PROSTAGLANDIN F2 ALPHA IS A PRODUCT OF THE DECIDUALIZED HUMAN STROMAL CELL.. FERTILITY AND STERILITY. S298-S298.
2013

Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 20:930-935.
Full Text via DOI: 10.1097/gme.0b013e3182a14372 PMID: 23942247
2013

TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies. CONTRACEPTION. 88:387-395.
Full Text via DOI: 10.1016/j.contraception.2012.11.022 PMID: 23312930
2013

EFFECTS OF MELOXICAM, A SEMI-SELECTIVE CYCLO-OXYGENASE 2 (COX-2) INHIBITOR, ON THE ULTRASOUND APPEARANCE OF THE DOMINANT FOLLICLE BEFORE AND AFTER THE LUTEINIZING HORMONE (LH) SURGE. CONTRACEPTION. 312-312.
2013

Ethinyl estradiol and 17 beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. CONTRACEPTION. 706-727.
Full Text via DOI: 10.1016/j.contraception.2012.12.011 PMID: 23375353
2013

Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. CONTRACEPTION. 87:738-743.
Full Text via DOI: 10.1016/j.contraception.2012.11.010 PMID: 23265980
2013

The importance of pharmacokinetic studies in drug development. CONTRACEPTION. 701-702.
Full Text via DOI: 10.1016/j.contraception.2013.04.004 PMID: 23668376
2013

Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. CONTRACEPTION. 87:744-749.
Full Text via DOI: 10.1016/j.contraception.2012.10.038 PMID: 23228503
2013

Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. CLIMACTERIC. 16:316-337.
Full Text via DOI: 10.3109/13697137.2013.795683 PMID: 23672656
2013

Weight gain during the menopause transition: which comes first, the chicken or the egg?. CLIMACTERIC. 296-297.
2013

Role of COX-2 in Decidualization of Endometrial Stromal Cells. REPRODUCTIVE SCIENCES. 228A-229A.
2013

Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. CLIMACTERIC. 16:17-27.
Full Text via DOI: 10.3109/13697137.2012.672495 PMID: 22646219
2013

Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. CONTRACEPTION. 87:201-211.
Full Text via DOI: 10.1016/j.contraception.2012.08.042 PMID: 23036478
2013

Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. CONTRACEPTION. 87:212-219.
Full Text via DOI: 10.1016/j.contraception.2012.10.009 PMID: 23158806
2013

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 20:47-56.
Full Text via DOI: 10.1097/gme.0b013e3182775fe9 PMID: 23266840
2013

Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 20:38-46.
Full Text via DOI: 10.1097/GME.0b013e318274699f PMID: 23266839
2013

Soil Diversity and Hydration as Observed by ChemCam at Gale Crater, Mars. SCIENCE. 341.
Full Text via DOI: 10.1126/science.1238670 PMID: 24072924
2012

Postmenopausal skin and estrogen. GYNECOLOGICAL ENDOCRINOLOGY. 2-6.
Full Text via DOI: 10.3109/09513590.2012.705392 PMID: 22849791
2012

SAFETY AND TOLERABILITY OF THE AGILE PATCH, A CONTRACEPTIVE PATCH WITH LOW-DOSE ETHINYL ESTRADIOL (EE) AND LEVONORGESTREL (LNG), VS. COMBINATION ORAL CONTRACEPTIVES (COCS) IN OBESE VS. NON-OBESE WOMEN. FERTILITY AND STERILITY. S195-S196.
2012

Vascular dysfunction as a cause of endometrial bleeding. GYNECOLOGICAL ENDOCRINOLOGY. 28:688-693.
Full Text via DOI: 10.3109/09513590.2011.588848 PMID: 22686262
2012

The use of isoflavinoids in menopausal health Reply. CLIMACTERIC. 407-408.
2012

Estrogen and progestogen effect on venous thromboembolism in menopausal women. CLIMACTERIC. 235-240.
Full Text via DOI: 10.3109/13697137.2012.664401 PMID: 22612609
2012

Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. CONTRACEPTION. 85:595-601.
Full Text via DOI: 10.1016/j.contraception.2011.10.006 PMID: 22133660
2012

Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 19:622-629.
Full Text via DOI: 10.1097/gme.0b013e31823b8867 PMID: 22282101
2012

Differential Pathways of Hemostasis and Fibrinolysis in Human Endometrial Endothelial Cells. REPRODUCTIVE SCIENCES. 228A-228A.
2012

SERUM ETHINYL ESTRADIOL LEVELS WITH A LOW-DOSE COMBINATION TRANSDERMAL CONTRACEPTIVE (AG200-15) COMPARED WITH A LOW-DOSE COMBINATION ORAL CONTRACEPTIVE. CONTRACEPTION. 318-318.
2011

Cardiovascular, Cerebrovascular and Hepatic Safety of Desvenlafaxine Over 1 Year in Women With Vasomotor Symptoms Associated With Menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1348-1348.
2011

Is There Ever an Indication for Hormone Therapy in an Asymptomatic Postmenopausal Woman?. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1339-1339.
2011

One-year Maintenance of Efficacy and Safety of Desvenlafaxine in Women With Vasomotor Symptoms Associated With Menopause. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1367-1367.
2011

Safety and Tolerability of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women: Findings From a 1-Year, Randomized, Placebo- and Active-controlled, Phase 3 Trial. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1355-1356.
2011

Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1355-1355.
2011

Delivery of therapeutic agents to the target tissue. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1040-1041.
Full Text via DOI: 10.1097/gme.0b013e31822ff238 PMID: 21926921
2011

Menopausal hot flushes and night sweats: where are we now?. CLIMACTERIC. 515-528.
Full Text via DOI: 10.3109/13697137.2011.608596 PMID: 21848495
2011

THYROID STIMULATING HORMONE (TSH) RECEPTOR ON GRANULOSA CELLS. FERTILITY AND STERILITY. S118-S118.
2011

TOLERABILITY OF DESVENLAFAXINE 100 MG IN WOMEN WITH VASOMOTOR SYMPTOMS (VMS) ASSOCIATED WITH MENOPAUSE: A POOLED ANALYSIS OF 5 TRIALS. FERTILITY AND STERILITY. S4-S5.
2011

Endogenous androgens and effects on body fat and insulin resistance. CLIMACTERIC. 405-406.
2011

Tailoring Combination Oral Contraceptives to the Individual Woman. JOURNAL OF WOMENS HEALTH. 20:879-891.
Full Text via DOI: 10.1089/jwh.2010.2199 PMID: 21631372
2011

Endometrial bleeding in postmenopausal women: with and without hormone therapy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 18:416-420.
Full Text via DOI: 10.1097/gme.0b013e31820ca808 PMID: 21701426
2011

Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. CLIMACTERIC. 14:282-288.
Full Text via DOI: 10.3109/13697137.2010.535226 PMID: 21244215
2011

Endogenous androgens and effects on body fat and insulin resistance. CLIMACTERIC. 405-406.
PMID: 21721175
2011

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 6-7.
Full Text via DOI: 10.1097/gme.0b013e318203a46b PMID: 21173718
2011

Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. CLIMACTERIC. 14:302-320.
Full Text via DOI: 10.3109/13697137.2011.570590 PMID: 21563996
2010

Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels A Randomized Controlled Trial. OBSTETRICS AND GYNECOLOGY. 116:1265-1273.
Full Text via DOI: 10.1097/AOG.0b013e3181fc3b1a PMID: 21099590
2010

High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1232-1233.
2010

Vaginal cytokines in postmenopausal women with symptoms of vulvovaginal irritation. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1243-1243.
2010

EVALUATION OF EXPOSURE TO ETHINYL ESTRADIOL (EE) WITH A LOW DOSE COMBINATION TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM (AG200-15) COMPARED TO LOW-DOSE COMBINATION ORAL CONTRACEPTIVE.. FERTILITY AND STERILITY. S4-S5.
2010

High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. GYNECOLOGICAL ENDOCRINOLOGY. 26:524-532.
Full Text via DOI: 10.3109/09513590903511547 PMID: 20459349
2010

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 95:S7-+.
Full Text via DOI: 10.1210/jc.2009-2509 PMID: 20566620
2010

A simple inexpensive screening test for endometrial abnormalities in asymptomatic women using tamoxifen. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 454-455.
Full Text via DOI: 10.1097/gme.0b013e3181dbf241 PMID: 20386342
2010

Desvenlafaxine: A therapeutic option for treatment of menopausal hot flashes. MATURITAS. 1-2.
Full Text via DOI: 10.1016/j.maturitas.2010.02.007 PMID: 20211532
2010

Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function. FERTILITY AND STERILITY. 93:1997-2003.
Full Text via DOI: 10.1016/j.fertnstert.2008.12.095 PMID: 19394598
2010

Beneficial effect of intravaginal DHEA in postmenopausal women suffering from vaginal atrophy and having identified pain at intercourse (dyspareunia) as their most bothersome symptom. ENDOCRINE JOURNAL. S526-S526.
2010

High efficacy of intravaginal DHEA on all symptoms and signs of vaginal atrophy. ENDOCRINE JOURNAL. S527-S527.
2010

Effect of intravaginal DHEA in postmenopausal women with vaginal atrophy and pain at sexual activity (dyspareunia) as most bothersome symptom. 13TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI) HELD JOINTLY WITH THE GERMAN SOCIETY OF OBSTETRICS & GYNECOLOGY. 233-238.
2010

Efficacy and tolerability of local estrogen therapy for urogenital atrophy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 194-203.
Full Text via DOI: 10.1097/gme.0b013e3181a95581 PMID: 19602990
2010

Tissue-Selective Estrogen Complexes A Promising Option for the Comprehensive Management of Menopausal Symptoms. DRUGS & AGING. 533-544.
Full Text via DOI: 10.2165/11316000-000000000-00000 PMID: 20583848
2010

Tissue-Selective Estrogen Complexes A Promising Option for the Comprehensive Management of Menopausal Symptoms. DRUGS & AGING. 533-544.
2009

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 16:1102-1108.
Full Text via DOI: 10.1097/gme.0b013e3181a816be PMID: 19546825
2009

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 16:1109-1115.
Full Text via DOI: 10.1097/gme.0b013e3181a818db PMID: 19543129
2009

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. FERTILITY AND STERILITY. 92:1039-1044.
Full Text via DOI: 10.1016/j.fertnstert.2009.05.093 PMID: 19635614
2009

Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 16:923-931.
Full Text via DOI: 10.1097/gme.0b013e31819e85c6 PMID: 19424093
2009

Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 16:907-922.
Full Text via DOI: 10.1097/gme.0b013e31819e8e2d PMID: 19436225
2009

Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. CONTRACEPTION. 80:245-253.
Full Text via DOI: 10.1016/j.contraception.2009.03.006 PMID: 19698816
2009

Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 16:897-906.
Full Text via DOI: 10.1097/gme.0b013e31819e8930 PMID: 19436226
2009

Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. CONTRACEPTION. 79:469-478.
Full Text via DOI: 10.1016/j.contraception.2008.12.010 PMID: 19442784
2009

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 200.
Full Text via DOI: 10.1016/j.ajog.2008.10.057 PMID: 19167693
2009

A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 200.
Full Text via DOI: 10.1016/j.ajog.2008.09.877 PMID: 19110224
2009

Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells. CONTRACEPTION. 79:139-145.
Full Text via DOI: 10.1016/j.contraception.2008.08.008 PMID: 19135572
2009

Menopausal hot flashes are treated effectively by a transdermal, low-dose estradiol spray. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM. 18-19.
Full Text via DOI: 10.1038/ncpendmet1024 PMID: 19079270
2009

Premature menopause increases cardiovascular risk. CLIMACTERIC. 12:26-31.
Full Text via DOI: 10.1080/13697130903013452 PMID: 19811237
2008

Intravaginal DHEA, the Physiological and Highly Efficient Treatment of Vaginal Atrophy. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1230-1230.
2008

Tailoring Progestogen Therapy for the Individual Patient. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1201-1201.
2008

Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users. CONTRACEPTION. 78:106-112.
Full Text via DOI: 10.1016/j.contraception.2008.04.003 PMID: 18672110
2008

Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 584-602.
Full Text via DOI: 10.1097/gme.0b013e31817b076a PMID: 18580541
2008

Effects of estradiol on synthesis, secretion, and activation of von Willebrand factor in endometrial endothelial cell. REPRODUCTIVE SCIENCES. 283A-283A.
2008

Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 198.
Full Text via DOI: 10.1016/j.ajog.2007.05.020 PMID: 18166301
2008

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. CLIMACTERIC. 11:63-73.
Full Text via DOI: 10.1080/13697130701852390 PMID: 18202966
2007

Clinical outcomes associated with new oral low-dose EPT. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 1080-1080.
2007

Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. FERTILITY AND STERILITY. 88:866-878.
Full Text via DOI: 10.1016/j.fertnstert.2006.12.052 PMID: 17548089
2007

Analysis of characteristics of women with early amenorrhea or persistent unscheduled bleeding with cycle-free LNG/EE, a continuous-use oral contraceptive (OC).. FERTILITY AND STERILITY. S256-S256.
2007

Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm - A randomized controlled trial. OBSTETRICS AND GYNECOLOGY. 110:577-586.
2007

Desvenlafaxine succinate (DVS) efficacy for the relief of vasomotor symptoms (VMS) associated with menopause: A double-blind, placebo-controlled trial.. FERTILITY AND STERILITY. S243-S243.
2007

Desvenlafaxine succinate (DVS), a novel serotonin and norepinephrine reuptake inhibitor, improves mood and menopausal symptoms in women with hot flushes (HFS) associated with menopause.. FERTILITY AND STERILITY. S246-S246.
2007

Effect of vascular endothelial growth factor (VEGF) withdrawal on apoptosis in an immortalized human endometrial endothelial cell (HEEC) line.. FERTILITY AND STERILITY. S51-S52.
2007

Endometrial and ovarian safety of bazedoxifene (BZA) in the prevention of postmenopausal osteoporosis.. FERTILITY AND STERILITY. S241-S242.
2007

Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-at mRNA in Ishikawa cells implication for tibolone's effects on the endometrium. MATURITAS. 57:338-346.
Full Text via DOI: 10.1016/j.maturitas.2007.03.002 PMID: 17478063
2007

Endometrial bleeding during hormone therapy: The effect of progestogens. MATURITAS. 57:71-76.
Full Text via DOI: 10.1016/j.maturitas.2007.02.022 PMID: 17412535
2007

Drospirenone, a progestin with added value for hypertensive postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 352-354.
Full Text via DOI: 10.1097/gme.0b013e31804d440b PMID: 17414576
2007

Desvenlafaxine succinate is effective in the treatment of menopausal vasomotor symptoms. OBSTETRICS AND GYNECOLOGY. 76S-77S.
2007

Effects of desvenlafaxine on sleep and mood in menopausal women - A pooled analysis. OBSTETRICS AND GYNECOLOGY. 77S-77S.
2007

Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. CLIMACTERIC. 10:120-131.
Full Text via DOI: 10.1080/13697130701298107 PMID: 17453860
2007

Endometrial effects of tibolone. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 92:911-918.
Full Text via DOI: 10.1210/jc.2006-2207 PMID: 17192288
2007

Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 168-182.
Full Text via DOI: 10.1097/gme.0b013e31803167ab PMID: 17259911
2007

Drospirenone and estradiol: a new option for the postmenopausal woman. CLIMACTERIC. 10:3-10.
Full Text via DOI: 10.1080/13697130601114859 PMID: 17364592
2007

Drospirenone-containing hormone therapy for postmenopausal women - Perspective on current data. JOURNAL OF REPRODUCTIVE MEDICINE. 52:159-164.
2007

Endometrial expression of epithelial neutrophil-activating peptide-78 during the menstrual cycle or in progestin-only contraceptive users with breakthrough bleeding and the influence of doxycycline therapy. HUMAN REPRODUCTION. 22:427-433.
Full Text via DOI: 10.1093/humrep/de1398
2007

The role of aldosterone in progression of hypertension - How it affects women in menopause. JOURNAL OF REPRODUCTIVE MEDICINE. 143-146.
2007

Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mu g (Loestrin (R) 24 Fe). CONTRACEPTION. 75:16-22.
Full Text via DOI: 10.1016/j.contraception.2006.08.004 PMID: 17161118
2007

Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 28-31.
Full Text via DOI: 10.1002/pds.1342 PMID: 17177322
2006

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. CONTRACEPTION. 74:439-445.
Full Text via DOI: 10.1016/j.contraception.2006.07.005 PMID: 17157099
2006

Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. CONTRACEPTION. 359-366.
Full Text via DOI: 10.1016/j.contraception.2006.06.003 PMID: 17046376
2006

Progesterone receptor modulator for emergency contraception - A randomized controlled trial. OBSTETRICS AND GYNECOLOGY. 108:1089-1097.
2006

FemCap (TM) with removal strap: ease of removal, safety and acceptability. CONTRACEPTION. 73:59-64.
Full Text via DOI: 10.1016/j.contraception.2005.06.074 PMID: 16371297
2005

Microarray analysis of genes related with angiogenesis in human endometrial cells trated with delta 4-tibolone and medroxyprogesterone acetate. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 786-786.
2005

Interleukin-1 beta,-2,-6, and -8 levels in serum and uterine cavity fluid during the normal luteal phase.. FERTILITY AND STERILITY. S26-S26.
2005

Progestogens: effects on clinical and biochemical parameters in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY. 484-487.
Full Text via DOI: 10.1097/01.gme.0000177319.31629.52 PMID: 16145299
2005

Raloxifene (Rix) effects on vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) are not mediated by changes in steroid receptor (SR) co-repressors or co-activators or cell proliferation markers in a human endometrial cell line.. FERTILITY AND STERILITY. S230-S230.
2005

Raloxifene (Rix) has antiestrogenic effect on vascular endothelial growth factor (VEGF) mRNA and protein while down-regulating progesterone receptors in a human endometrial cell line in vitro.. FERTILITY AND STERILITY. S229-S230.
2005

Raloxifene shows progestagenic effects on thrombospondin-1 (TSP-1) and down-regulation of progesterone receptors in a human endometrial cell line.. FERTILITY AND STERILITY. S119-S120.
2005

Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. FERTILITY AND STERILITY. 84:485-491.
Full Text via DOI: 10.1016/j.fertnstert.2005.01.129 PMID: 16084894
2005

Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. OBSTETRICS AND GYNECOLOGY. 105:1397-1404.
Full Text via DOI: 10.1097/01.AOG.0000163253.27610.b9 PMID: 15932835
2005

A contemporary approach to the menopause - Preface. SEMINARS IN REPRODUCTIVE MEDICINE. 115-116.
2005

Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. SEMINARS IN REPRODUCTIVE MEDICINE. 23:188-195.
2005

Safety and efficacy of Implanon (TM), a single-rod implantable contraceptive containing etonogestrel. CONTRACEPTION. 71:319-326.
Full Text via DOI: 10.1016/j.contraception.2004.11.007 PMID: 15854630
2005

Doxycycline alters the expression profile of proinflammatory cytokines and chemokines in human endometrial cells.. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION. 168A-168A.

research overview

Medications used in women's health both preventive and therapeutic. Hormone therapy in menopause, contraceptive methods for women and men, interventions for treating uterine fibroids with and without heavy menstrual bleeding, endometriosis, and unscheduled vaginal bleeding during use of hormonal contraception are major clinical areas of interest. Basic research involving the evaluation of the plasminogen activator system in the endometrium of women with a focus on the endometrial endothelial cells.